Fact checked byMindy Valcarcel, MS

Read more

December 24, 2024
1 min read
Save

Memorial Sloan Kettering names hematologic malignancies division head

Fact checked byMindy Valcarcel, MS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ivan Maillard, MD, PhD, has been appointed head of the division of hematologic malignancies at Memorial Sloan Kettering Cancer Center.

Maillard is recognized for his expertise treating lymphoma and leukemia, with focuses on bone marrow transplantation, hematopoiesis, lymphoid biology and Notch signaling.

Quote from Ivan Maillard, MD, PhD

“It is an honor to join this impressive group of colleagues at an institution with a storied history of contributions to the field of oncology,” Maillard said in a press release. “I look forward to learning from my peers and working together to identify new partnerships, innovative treatment approaches, and more — all while remaining focused on providing cutting-edge care that is personalized for everyone who comes to [Memorial Sloan Kettering].”

Maillard succeeds Gilles Salles, MD, PhD, who served as acting head of the division of hematologic malignancies for the past year.

Maillard most recently served as Kevin Reitnauer Fox professor of oncology at University of Pennsylvania. He served as vice chief for research in the division of hematology/oncology, as well as investigator with Abramson Family Cancer Research Institute at University of Pennsylvania, since 2018. He also served as co-scientific director of University of Pennsylvania’s cell therapy and transplantation program.

He led University of Michigan’s leukemia program from 2014 to 2017.

“Dr. Maillard approaches his clinical care and research in a holistic manner,” Deb Schrag, MD, MPH, chair of the department of medicine at Memorial Sloan Kettering, said in a press release. “The combination of his career-long focus on mentorship, basic and translational investigation, and patient care makes him the optimal person to lead [Memorial Sloan Kettering’s] division of hematologic malignancies into the future. We are confident that he will serve as a staunch ally and supporter of our faculty members, working with them to identify paths to career development, address roadblocks, and maximize creativity and potential of those within the division.”